Edition:
India

Compugen Ltd (CGEN.OQ)

CGEN.OQ on NASDAQ Stock Exchange Global Market

4.29USD
18 Sep 2019
Change (% chg)

$-0.04 (-0.92%)
Prev Close
$4.33
Open
$4.30
Day's High
$4.30
Day's Low
$4.23
Volume
9,568
Avg. Vol
34,797
52-wk High
$4.36
52-wk Low
$2.00

Latest Key Developments (Source: Significant Developments)

Compugen Reports Qtrly Loss Per Share $0.14
Monday, 20 May 2019 

May 20 (Reuters) - Compugen Ltd ::COMPUGEN REPORTS FIRST QUARTER 2019 RESULTS.COMPUGEN LTD - QTRLY LOSS PER SHARE $0.14.  Full Article

Compugen Issues 2 U.S. Composition Of Matter Patents For COM701, Its Immuno-Oncology Product Candidate
Tuesday, 12 Mar 2019 

March 12 (Reuters) - Compugen Ltd ::COMPUGEN ANNOUNCES ISSUANCE OF TWO U.S. COMPOSITION OF MATTER PATENTS FOR COM701, ITS LEAD IMMUNO-ONCOLOGY PRODUCT CANDIDATE.COMPUGEN - PATENT WHICH COVERS COMPOSITION COMPRISING COM701 AND BACKUP ANTIBODIES, IS EXPECTED TO EXPIRE NO EARLIER THAN AUGUST 2037 IN UNITED STATES.  Full Article

Compugen Posts Q4 Loss Per Share $0.16
Tuesday, 26 Feb 2019 

Feb 26 (Reuters) - Compugen Ltd ::COMPUGEN REPORTS FOURTH QUARTER AND FULL YEAR 2018 RESULTS AND ANNOUNCES CORPORATE RESTRUCTURING TO STREAMLINE OPERATIONS.Q4 LOSS PER SHARE $0.16.RESTRUCTURING INCLUDES CONSOLIDATION OF RESEARCH AND DEVELOPMENT ACTIVITIES IN ONE LOCATION (ISRAEL).POSITIONS AND OPERATIONS ELIMINATED WILL ALSO REDUCE OVERLAPPING RESEARCH AND DEVELOPMENT AND G&A ACTIVITIES IN ISRAEL AND UNITED STATES.RESTRUCTURING INCLUDES A 35% WORKFORCE REDUCTION (APPROXIMATELY 35 EMPLOYEES), MAJORITY OF WHICH IS IN RESEARCH AND DEVELOPMENT.CERTAIN PRECLINICAL ACTIVITIES WILL BE OUTSOURCED TO THIRD-PARTY SERVICE PROVIDERS.COMPUGEN ANTICIPATES SAVINGS OF UP TO $10 MILLION ON AN ANNUAL BASIS.BASED ON CURRENT CASH,ANTICIPATED SAVINGS RESULTING FROM RESTRUCTURING ACTIVITIES, CO EXPECTS CASH RUNWAY TO EXTEND THROUGH MID-2020.COMPUGEN -SEES CASH EXPENDITURES FOR 2019 INCLUDING ONE-TIME RESTRUCTURING RELATED COSTS, IN RANGE OF $27 TO $29 MILLION, WITH FULL EFFECT OF SAVINGS REFLECTED IN 2020.  Full Article

Compugen Q3 Loss Per Share $0.05
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Compugen Ltd ::COMPUGEN REPORTS THIRD QUARTER 2018 RESULTS.Q3 LOSS PER SHARE $0.05.Q3 REVENUE $7.8 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.20, REVENUE VIEW $0.00 -- THOMSON REUTERS I/B/E/S.  Full Article

Compugen Announces Clinical Milestone Payment In Cancer Immunotherapy Collaboration With Bayer
Thursday, 20 Sep 2018 

Sept 20 (Reuters) - Compugen Ltd ::COMPUGEN ANNOUNCES CLINICAL MILESTONE PAYMENT IN CANCER IMMUNOTHERAPY COLLABORATION WITH BAYER FOLLOWING DOSING OF FIRST PATIENT IN BAY 1905254 PHASE 1 TRIAL.COMPUGEN LTD - UNDER TERMS OF COLLABORATION AND LICENSE AGREEMENT, CO IS ENTITLED TO A MILESTONE PAYMENT OF $7.8 MILLION AT FIRST PATIENT DOSING.  Full Article

Compugen's Q2 Loss Per Share $0.19
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Compugen Ltd ::COMPUGEN REPORTS SECOND QUARTER 2018 RESULTS.Q2 LOSS PER SHARE $0.19.  Full Article

Compugen Announces FDA Clearance Of IND Application For COM701, A First-In-Class Immuno-Oncology Therapeutic Antibody
Monday, 2 Jul 2018 

July 2 (Reuters) - Compugen Ltd ::COMPUGEN ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR COM701, A FIRST-IN-CLASS IMMUNO-ONCOLOGY THERAPEUTIC ANTIBODY.  Full Article

Compugen Reports Q1 Revenue Of $10 Million
Wednesday, 9 May 2018 

May 9 (Reuters) - Compugen Ltd ::COMPUGEN REPORTS FIRST QUARTER 2018 RESULTS.Q1 EARNINGS PER SHARE $0.00.Q1 REVENUE $10 MILLION.  Full Article

COMPUGEN REPORTS Q3 LOSS PER SHARE $0.19
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Compugen Ltd ::COMPUGEN REPORTS THIRD QUARTER 2017 RESULTS.Q3 LOSS PER SHARE $0.19.‍AS OF SEPTEMBER 30, 2017, CASH AND CASH RELATED ACCOUNTS TOTALED $38.5 MILLION, COMPARED WITH $61.5 MILLION AS OF DECEMBER 31, 2016​.  Full Article

Compugen to initiate manufacturing of COM902
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Compugen Ltd :Compugen Ltd - ‍advancing COM902 into manufacturing in anticipation of filing an investigational new drug (IND) application in 2019​.Compugen Ltd - ‍entered into process development and manufacturing service agreement with Bayer Healthcare LLC (Bayer) to produce COM902.Compugen Ltd - ‍working towards filing IND for COM902 in 2019​.  Full Article